MX2022003193A - Tratamiento de encefalopatia asociada al gen syngap1. - Google Patents
Tratamiento de encefalopatia asociada al gen syngap1.Info
- Publication number
- MX2022003193A MX2022003193A MX2022003193A MX2022003193A MX2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A MX 2022003193 A MX2022003193 A MX 2022003193A
- Authority
- MX
- Mexico
- Prior art keywords
- syngap1
- encephalopathy
- treatment
- subject
- cannabidiol
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title abstract 2
- 208000032274 Encephalopathy Diseases 0.000 title abstract 2
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 abstract 2
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 abstract 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 2
- 229950011318 cannabidiol Drugs 0.000 abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Acoustics & Sound (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente tecnología se relaciona a métodos para tratar la encefalopatía asociada al gen SINGAP1 por administrar transdérmicamente una cantidad efectiva de cannabidiol (CBD) al sujeto, en donde se trata un síntoma asociado al gen SINGAP1 en el sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901651P | 2019-09-17 | 2019-09-17 | |
| PCT/US2020/051095 WO2021055493A1 (en) | 2019-09-17 | 2020-09-16 | Treatment of syngap1 encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003193A true MX2022003193A (es) | 2022-04-11 |
Family
ID=74869217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003193A MX2022003193A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de encefalopatia asociada al gen syngap1. |
| MX2022003194A MX2022003194A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003194A MX2022003194A (es) | 2019-09-17 | 2020-09-16 | Tratamiento de deterioro del comportamiento en la encefalopatia del desarrollo y epileptica. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210077421A1 (es) |
| EP (2) | EP4031119A4 (es) |
| JP (2) | JP2022547136A (es) |
| KR (2) | KR20220066091A (es) |
| CN (2) | CN114423416A (es) |
| AU (2) | AU2020350605A1 (es) |
| BR (2) | BR112022004272A2 (es) |
| CA (2) | CA3151171A1 (es) |
| IL (2) | IL291362A (es) |
| JO (2) | JOP20220061A1 (es) |
| MX (2) | MX2022003193A (es) |
| WO (2) | WO2021055499A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| AU2020366147B2 (en) | 2019-10-14 | 2024-09-05 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| IL303388A (en) * | 2020-12-03 | 2023-08-01 | Zynerba Pharmaceuticals Inc | Treatment of refractory convulsions |
| CN116829135A (zh) * | 2021-01-28 | 2023-09-29 | Zyne制药公司 | 大麻二酚对睡眠呼吸暂停的治疗 |
| JP2024514843A (ja) * | 2021-04-08 | 2024-04-03 | パイク セラピューティクス インコーポレイテッド | 発作性疾患を治療するための医薬組成物及び方法 |
| US20230265436A1 (en) * | 2022-02-24 | 2023-08-24 | Q-State Biosciences, Inc. | Therapeutics for syngap haploinsufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2531278A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| EP3653712B1 (en) * | 2015-02-04 | 2022-11-30 | F. Hoffmann-La Roche AG | Tau antisense oligomers and uses thereof |
| US10716766B2 (en) * | 2015-03-02 | 2020-07-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| IL246790A0 (en) * | 2016-07-14 | 2016-09-29 | Friedman Doron | Self-dissolving compounds of cannabinoids |
| EP3684411A1 (en) * | 2017-09-19 | 2020-07-29 | Zynerba Pharmaceuticals, Inc. | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults |
| CA3080434A1 (en) * | 2017-10-30 | 2019-05-09 | Endocanna Health, Inc. | Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations |
| GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
-
2020
- 2020-09-16 US US17/022,494 patent/US20210077421A1/en active Pending
- 2020-09-16 BR BR112022004272A patent/BR112022004272A2/pt unknown
- 2020-09-16 KR KR1020227011640A patent/KR20220066091A/ko unknown
- 2020-09-16 EP EP20864502.8A patent/EP4031119A4/en active Pending
- 2020-09-16 CN CN202080065120.3A patent/CN114423416A/zh active Pending
- 2020-09-16 WO PCT/US2020/051102 patent/WO2021055499A1/en active Application Filing
- 2020-09-16 JO JOP/2022/0061A patent/JOP20220061A1/ar unknown
- 2020-09-16 KR KR1020227011639A patent/KR20220063208A/ko unknown
- 2020-09-16 JP JP2022515027A patent/JP2022547136A/ja active Pending
- 2020-09-16 CA CA3151171A patent/CA3151171A1/en active Pending
- 2020-09-16 AU AU2020350605A patent/AU2020350605A1/en active Pending
- 2020-09-16 CA CA3150617A patent/CA3150617A1/en active Pending
- 2020-09-16 BR BR112022004175A patent/BR112022004175A2/pt unknown
- 2020-09-16 JP JP2022515014A patent/JP2022547922A/ja active Pending
- 2020-09-16 CN CN202080065085.5A patent/CN114401713A/zh active Pending
- 2020-09-16 JO JOP/2022/0054A patent/JOP20220054A1/ar unknown
- 2020-09-16 EP EP20866006.8A patent/EP4031120A4/en active Pending
- 2020-09-16 AU AU2020348310A patent/AU2020348310A1/en active Pending
- 2020-09-16 MX MX2022003193A patent/MX2022003193A/es unknown
- 2020-09-16 WO PCT/US2020/051095 patent/WO2021055493A1/en active Application Filing
- 2020-09-16 MX MX2022003194A patent/MX2022003194A/es unknown
-
2022
- 2022-03-14 IL IL291362A patent/IL291362A/en unknown
- 2022-03-14 IL IL291363A patent/IL291363A/en unknown
- 2022-03-17 US US17/697,629 patent/US20220218625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20220054A1 (ar) | 2023-01-30 |
| MX2022003194A (es) | 2022-04-11 |
| EP4031120A1 (en) | 2022-07-27 |
| KR20220066091A (ko) | 2022-05-23 |
| US20210077421A1 (en) | 2021-03-18 |
| CA3150617A1 (en) | 2021-03-25 |
| BR112022004272A2 (pt) | 2022-06-07 |
| EP4031119A1 (en) | 2022-07-27 |
| IL291362A (en) | 2022-05-01 |
| WO2021055493A1 (en) | 2021-03-25 |
| BR112022004175A2 (pt) | 2022-05-31 |
| US20220218625A1 (en) | 2022-07-14 |
| IL291363A (en) | 2022-05-01 |
| CA3151171A1 (en) | 2021-03-25 |
| JOP20220061A1 (ar) | 2023-01-30 |
| CN114401713A (zh) | 2022-04-26 |
| EP4031120A4 (en) | 2023-08-02 |
| WO2021055499A1 (en) | 2021-03-25 |
| JP2022547922A (ja) | 2022-11-16 |
| JP2022547136A (ja) | 2022-11-10 |
| AU2020348310A1 (en) | 2022-03-31 |
| KR20220063208A (ko) | 2022-05-17 |
| CN114423416A (zh) | 2022-04-29 |
| EP4031119A4 (en) | 2023-08-02 |
| AU2020350605A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220054A1 (ar) | علاج اعتلال الدماغ syngap1 | |
| MX2022012424A (es) | Tratamiento del sindrome del cromosoma x fragil con canabidiol. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| MX2024002904A (es) | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| MX2020005547A (es) | Moduladores de la actividad del complemento. | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| AU2016255707A8 (en) | Uses of cannabidiol for treatment of infantile spasms | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| TN2019000019A1 (en) | Treatment and prevention of sleep disorders | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| MX2021003006A (es) | Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne. | |
| MX2023006551A (es) | Tratamiento de las convulsiones refractarias. | |
| JOP20220310A1 (ar) | علاج اضطراب طيف التوحد بكانابيديول | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| MX2023008876A (es) | Tratamiento de la apnea del sueño con cannabidiol (cbd). | |
| MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. | |
| WO2020061067A3 (en) | Compositions and methods for treating bone injury | |
| MX2022005158A (es) | Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc). |